COYA
Coya Therapeutics, Inc.
Key Financials
Revenue
$7.9M
↑ 123.6%
EPS (Diluted)
$-1.27
↓ 29.6%
Shareholders' Equity
$43.0M
↑ 8.7%
Total Assets
$50.0M
↑ 12.6%
Total Liabilities
$6.9M
↑ 45.1%
Cash & Equivalents
$46.8M
↑ 22.1%
Operating Income
$-22555225
↓ 30.8%
Net Income
$-21226107
↓ 42.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/9/2026 | View on SEC |
| 3 | 4/9/2026 | View on SEC |
| 8-K | 4/2/2026 | View on SEC |
| EFFECT | 3/20/2026 | View on SEC |
| 424B3 | 3/20/2026 | View on SEC |
| S-3 | 3/16/2026 | View on SEC |
| 10-K | 3/16/2026 | View on SEC |
| 8-K | 3/16/2026 | View on SEC |
| SCHEDULE 13G | 3/12/2026 | View on SEC |
| SCHEDULE 13G/A | 1/30/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | COYA |
| Company Name | Coya Therapeutics, Inc. |
| CIK | 1835022 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650.739.3939 |